文献速递胸部病理细胞病理与分子病理

下一代测序及其他多基因突变检测的一致性:全球环状试验研究

Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
PubMed 文献 · Cancer Cytopathol · 2017-05-05

该全球环状试验使用携带EGFR、KRAS、NRAS、BRAF和PIK3CA突变的定量细胞学分子参考玻片,评估14家机构多基因突变检测的一致性。使用NGS的11家实验室在10%和5%稀释点变异分数均值与标准误差异极小(P=.171和P=.063),但1%低等位基因频率时一致性低,不同阈值影响结果。MALDI-TOF实验室一致性较低。

要点

  • 1%低等位基因频率时NGS结果一致性低,与各机构变异调用阈值不同有关。
  • 定量分子参考玻片可用于监测多基因突变检测性能并促进标准化。

核心结论

  • 定量分子参考玻片是监测多基因突变检测性能的有用工具,有助于分子细胞病理学流程的标准化。

研究设计与样本

  • 全球14家机构参与环状试验,对携带EGFR、KRAS、NRAS、BRAF和PIK3CA不同等位基因比例突变的定量细胞学分子参考玻片进行多基因突变检测。
  • 各实验室使用自身突变分析平台和方法,从组织提取到数据分析。

主要发现

  • 使用NGS的11家实验室在10%稀释点变异分数均值与标准误差异无统计学意义(P=.171)。
  • 使用NGS的11家实验室在5%稀释点变异分数均值与标准误差异无统计学意义(P=.063)。
  • 1%低等位基因频率时NGS结果一致性低,反映各机构变异调用阈值不同。
  • 使用MALDI-TOF的2家实验室在突变检测和突变等位基因频率定量方面一致性较低。

关键数值与推荐

  • NGS平台包括Illumina、Ion Torrent/Proton和Roche,在10%和5%稀释点变异分数差异P值分别为.171和.063。
  • 低等位基因频率1%时NGS结果一致性低。
  • MALDI-TOF实验室(n=2)突变检测和突变AF定量一致性较低。

临床怎么用

  • 定量分子参考玻片可用于评估和监测多基因突变检测的性能。
  • 实验室应注意低等位基因频率(如1%)时变异调用阈值对一致性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular testing of cytological lung cancer specimens includes, beyond epidermal growth factor receptor (EGFR), emerging predictive/prognostic genomic biomarkers such as Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral [v-ras] oncogene homolog (NRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA). Next-generation sequencing (NGS) and other multigene mutational assays are suitable for cytological specimens, including smears. However, the current literature reflects single-institution studies rather than multicenter experiences. METHODS: Quantitative cytological molecular reference slides were produced with cell lines designed to harbor concurrent mutations in the EGFR, KRAS, NRAS, BRAF, and PIK3CA genes at various allelic ratios, including low allele frequencies (AFs; 1%). This interlaboratory ring trial study included 14 institutions across the world that performed multigene mutational assays, from tissue extraction to data analysis, on these reference slides, with each laboratory using its own mutation analysis platform and methodology. RESULTS: All laboratories using NGS (n = 11) successfully detected the study's set of mutations with minimal variations in the means and standard errors of variant fractions at dilution points of 10% (P = .171) and 5% (P = .063) despite the use of different sequencing platforms (Illumina, Ion Torrent/Proton, and Roche). However, when mutations at a low AF of 1% were analyzed, the concordance of the NGS results was low, and this reflected the use of different thresholds for variant calling among the institutions. In contrast, laboratories using matrix-assisted laser desorption/ionization-time of flight (n = 2) showed lower concordance in terms of mutation detection and mutant AF quantification. CONCLUSIONS: Quantitative molecular reference slides are a useful tool for monitoring the performance of different multigene mutational assays, and this could lead to better standardization of molecular cytopathology procedures. Cancer Cytopathol 2017;125:615-26. © 2017 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, et al. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathol. 2017. PMID: 28475299. doi:10.1002/cncy.21868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。